ZyVersa Therapeutics (ZyVersa Therapeutics) Operating Cash Flow per Share : $-31.45 (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is ZyVersa Therapeutics Operating Cash Flow per Share?

ZyVersa Therapeutics's operating cash flow per share for the three months ended in Mar. 2024 was $-6.05. ZyVersa Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-31.45.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -6.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for ZyVersa Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

ZVSA' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -6.3 Med: -6.3 Max: -6.3
Current: -6.3

During the past 4 years, ZyVersa Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was -6.30% per year. The lowest was -6.30% per year. And the median was -6.30% per year.

ZVSA's 3-Year OCF Growth Rate is ranked worse than
62.85% of 1233 companies
in the Biotechnology industry
Industry Median: 3.3 vs ZVSA: -6.30

ZyVersa Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for ZyVersa Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZyVersa Therapeutics Operating Cash Flow per Share Chart

ZyVersa Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

-74.06

-87.52

-21.67

-88.99

ZyVersa Therapeutics Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial								-176.50	-8.00	-10.52	-6.88	-6.05

Competitive Comparison of ZyVersa Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, ZyVersa Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ZyVersa Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ZyVersa Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where ZyVersa Therapeutics's Price-to-Operating-Cash-Flow falls into.

ZyVersa Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

ZyVersa Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-8.721	/	0.098
	=	-88.99

ZyVersa Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-3.777	/	0.624
	=	-6.05

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.45

ZyVersa Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of ZyVersa Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

ZyVersa Therapeutics (ZyVersa Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ZyVersa Therapeutics Inc (NAS:ZVSA) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

2200 North Commerce Parkway, Suite 208, Weston, FL, USA, 33326

Website

https://www.zyversa.com

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are 1) Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. 2) IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

Executives

Pablo A. Guzman	officer: Chief Medical Officer	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Gregory Gene Freitag	director	13631 PROGRESS BLVD., ALACHUA FL 32615
Katrin Rupalla	director	10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
James Sapirstein	director	1517 SAN JACINTO, HOUSTON TX 77002
Stephen C. Glover	director, officer: Chief Executive Officer	108 DOCKSIDE CIRCLE, WESTON FL 33327
Labella Nicholas A. Jr.	officer: Chief Scientific Officer	C/O INSMED INCORPORATED, 8720 STONY POINT PKWY, SUITE 200, RICHMOND VA 23235
Peter Wolfe	officer: Chief Financial Officer	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Karen A. Cashmere	officer: Chief Commercial Officer	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Min-chul Park	director	C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326
Incon Co., Ltd.	10 percent owner	4/F 16-17 LS-RO 91BEON-GIL, DONGAN-GU ANYANG, GYEONGGI M5 14042
Robert G Finizio	director	951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Raj Mehra	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
David S. Briones	director, officer: Chief Financial Officer	C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Daniel J. O'connor	director, officer: Chief Executive Officer	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
A.g.p. / Alliance Global Partners Corp.	10 percent owner	88 POST ROAD WEST, 2ND FLOOR, WESTPORT CT 06880